Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I agree to the Terms of Use , Privacy Notice and Cookie ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The U.S. stock market has experienced a volatile period, with major indices like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing varied performance amid ongoing trade tensions and ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies ...

What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader and Terry Chrisomalis give us their picks. BridgeBio (NASDAQ:BBIO) also has a healthy late-stage ...

What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader and Terry Chrisomalis  give us their picks. ONeil Trader: BridgeBio (NASDAQ:BBIO) is my highest ...

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive ...